Join MAPS on LinkedIn to further build your professional connections within Medical Affairs through our Company and Group Pages.
Follow us on Twitter and say abreast of MAPS activities and key issues for Medical Affairs professionals.
Stephen Dodge, PharmD, MBA
Associate Vice President – Field Medical Affairs
Mark Cziraky, PharmD
Vice President of Research
Mark LaLeike, MS
Josephine Li-McCleod, RPh, PhD
Chief Strategy Officer
Traditionally, Medical Affairs has had a very targeted role in conversations with payer organizations, working primarily to communicate clinical and scientific content. The relationships between the pharmaceutical/biotech industry and payer organizations continues to evolve; and Medical Affairs is positioned to take on a greater role in the conversation to ensure patients have appropriate access to novel therapies. As the availability and understanding of real world data grows both payers and manufacturers struggle with how to improve patient access while managing cost to the healthcare system. We have seen manufacturers invest in RWE programs expecting benefits in market access and have also seen payers not consider these data in their reimbursement decisions. To provide more value from these research efforts, we believe that Medical Affairs teams should strengthen their understanding of payer perspectives and their consideration of RWE in reimbursement decisions. This workshop focuses on providing additional context and case examples directly related to health economics and market access for commercial payers in the US.
At the end of this session, attendees will be able to:
[mepr-show if=”rule: 4078″]
[mepr-hide if=”rule: 4078″]
Your subscription has expired. To view this content, please visit your account page to purchase a new subscription.
Please login or purchase a membership to view this content.